INDIANAPOLIS — Eli Lilly and Company plans to create 100 new jobs by investing $400 million in manufacturing facilities at its Lilly Technology Center campus in Indianapolis.
The company announced they plan to invest the money in enhancements to existing manufacturing facilities used to make insulin and other diabetes medications, and initial capital investments to manufacture future medicines, according to a press release from the company.
“These investments demonstrate Lilly’s commitment to our manufacturing footprint in Indiana and the United States, and have been made possible by the tax reform measures passed by Congress in 2017,” David A. Ricks, Eli Lilly’s chairman and chief executive officer, said in a press release. "This is crucial for us to continue to advance our state’s economy and drive future investment – adding high-tech jobs and facilities that keep Indiana competitive in the global marketplace.”
Because of the increase in capabilities, Eli Lilly says they will need to hire more people to fill highly skilled manufacturing jobs.
“To make medicine, we need highly skilled technicians, scientists and engineers, who are economic catalysts for local communities,” Myles O’Neill, senior vice president and president of Manufacturing Operations, said in the release.
Since 2012, Eli Lilly says they have invested $5 billion in the U.S. and almost $2 billion in manufacturing diabetes medicines.
